Mutual Funds · Stocks

Reason to sell!! Find aplenty

Reason to sell!! Find aplenty
Rithholtz Presentation
Economy

Energy cost

Rain Industries
New trend · Technology

Metaverse and Apollo Group

Businessline
Chemicals

An insight into API Manufacturer

Disclaimer – Below Analysis is NOT a BUY/SELL/HOLD Recommendation. It is for educational purpose and it can be used for educational purposes further. There could be lot of things which might have been missed in my analysis either due to lack of information or oversight etc.. Do your own diligence & contact your expert financial adviser before making any investment decision.

Supriya Lifesciences – CMP 386 (Dated 24-02-2022)

Supriya Lifescience Limited got incorporated in the year 2008 and became one of the key Indian manufacturers and the supplier of APIs.

Business 

Supriya sells 38 API focused on the diverse therapeutic segments, along with being the largest exporter of Chlorphenamine Maleate, Salbutamol Sulphate, Ketamine Hydrochloride and Esketamine from India.

Supriya Lifescience is a pioneer in segments like antihistamine, analgesic, anesthetic, vitamin and anti-asthmetic and anti-allergic.

Region of operation

Company is focused on regulated markets and company is more export oriented with 77% revenues coming from exports

FY22

END USER INDUSTRIESKind of evergreen and growing industries in coming decade

  • Antihistamine
  • Anti-allergic
  • Anesthetic
  • Antiasthmatic and
  • Vitamin therapy

Moats

Backward integrated business model with well established presence in the API manufacturing, with focus on high value products with limited competition. Backward integration of top 12 products generating 67% of revenues thus de-risking many issues on supplies, pricing

Niche product basket of 38 APIs across diverse therapeutic segments

Advanced manufacturing and research and development capabilities with ability to handle complex chemistries across varied chain of reactions

Strengths

Pioneer in segments like antihistamine, analgesic, anesthetic, vitamin and anti-asthmetic and anti-allergic and clear leader in top three products having more than 50% share

Diversified export profile –Exports to 86 countries

Global clientele with long standing relationships on the back of consistent product quality & reliability of supply

Diversified therapeutic categories

USFDA, EUDQ, EUGMP, NMPA, CEP grants and approvals in place

Experienced senior management team and qualified operational personnel with new generation started in company already

Shareholding

Promoter has sufficient skin in game with holding ~68% and other prominent players in DII/FII holding 18% more leaving only 13-14% to general public

Some triggers and updates from recent Q3Fy22 Concall

Getting portfolio derisked and adding more categories which are complementing existing therapies

Expansion of manufacturing capability and capacity, scaling of existing molecules and addition of new products

Entering CDMO space

Growth in European region

Q4FY22 inputs from company

Risks (tried to see major risks, please do due diligence to understand more on this part)

Company earnings are quarter dependent with some quarters showing better growth than other quarters, it will take company few years to balance this up and down quarters with new products filling up

Export oriented risks ( freight risks, currency risks, geographical risks)

Risks associated with pharma companies on USFDA etc. kind of approvals

Any delay in CMO, CDMO projects ramp up which is expected by Q2FY24 (Aug-Sep 2023)

Any delay in ramping up Amber Nath facility (expected Dec2022)

Any sell off by FII/DII can lead to quick price erosion

Financials

Company is showing Good revenue growth with increasing Gross margins and reducing Debt to equity profile

Valuations

Current valuation look to factor in immediate growth for 1-2 quarters but if we keep our horizon long and vision as shared by company, then valuations seems reasonable (estimated PE of 16-19 Q1FY23E with CMP 386). Increasing capacity utilization and profitability can lead to rerating of company

Your strategy can be different than mine. Your selection of company might be different than mine. So lets not be a BLIND FOLLOWER

Disclaimer – Analysis is NOT a BUY/SELL/HOLD Recommendation. It is for educational purpose and it can be used for educational purposes further. There could be lot of things which might have been missed in my analysis either due to lack of information or oversight etc.. Do your own diligence & contact your expert financial adviser before making any investment decision.

In case you have any questions/ queries, please feel free to reach me through Contact Form

Do spread the word among your peers, family members or anyone who can benefit from this blog and asked them to subscribe. But be selfish and take care of yourself first by subscribing before they do.

Enjoy the day and your life. Don’t forget, we are alone in this grand universe and may not get a chance to live again.

New trend · Technology

Infosys and Metaverse Foundry

Infosys and Metaverse Foundry
Businessline
IPO

Soan Papdi : I am not going away

DHRP : Bikaji Foods
Medical

Growing Market

Goal Based Investing · Investing

Eliminate

Technology

Hexaware towards NFT Metaverse

Hexaware towards NFT Metaverse
Startups

10club house of brands

10club house of brands
Forbesindia
Environment · Stocks

Green metal

Businessline
Economy

Record hiring in IT

Stocks

Sequent : Worst behind!!

Sequent : Worst behind!!
Stocks

High Entry Barriers

High Entry Barriers
Technology · Travel

AI driven monetization

AI driven monetization
Company presentation Rategain
Technology

Betting on Technology

Betting on Technology
Business Line
Economy

Hiring index showing way forward

Hiring index showing way forward
Business Line
Hiring index showing way forward
Business Line
Automobiles

First signs of easing coming : Semiconductor chips

First signs of easing coming : Semiconductor chips
Technology

Technology trends in future

Technology trends in future
Investor presentation
Stocks

ROCE century: Redington

Medical · Medicine · Medium Term trend

E-pharmacy vs retail

Source : Frost and Sullivan report
Disruption · Technology

Li-ion Batteries growth estimation in India

Automobiles · Disruption

Semiconductors : Structural theme underway!

Learning · Risks

Superfast board meeting!! 10 min delivery

Automobiles

Will Auto sector revert to mean!

Environment

Hydrogen Electrolyzers running

Alternative assets · Tax calculations · Wealth destruction

TDS in Crypto ecosystem

Commodities · Economy · Environment · Green Energy

Critical Minerals for transition to Low Carbon economy

While steel will be crucial as an infrastructure enabler for all technological transition, specific elements will play an important role in each technology.
Chemicals

An insight into Speciality chemical company

Disclaimer – Below Analysis is NOT a BUY/SELL/HOLD Recommendation. It is for educational purpose and it can be used for educational purposes further. There could be lot of things which might have been missed in my analysis either due to lack of information or oversight etc.. Do your own diligence & contact your expert financial adviser before making any investment decision.

Tatva Chintan – CMP 2520 (Dated 3-feb-22)

Incorporated in 1996, Tatva Chintan Pharma Chem Limited is a specialty chemicals manufacturing company. It is engaged in the manufacture of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical & agrochemical intermediates & other specialty chemicals (PASC).

Business 

One of the leading producers with entire range of PTCs in India and one of the key producers across the globe

2nd largest manufacturer of SDAs for Zeolites globally and the largest commercial supplier in India

TCPCL is the largest producer of Glymes in India and third largest in the world.

Largest producer of electrolyte salts for super capacitor batteries in India

END USER INDUSTRIESGrowing industries in coming decade

  • Pharmaceutical API’s
  • Flavors and Fragrances
  • Agrochemicals
  • Environment Control Processes -NOx removal
  • Automotive – Catalytic Converter – Emission Control
  • Petrochemicals – Cracking crude
  • Automotive Transport & Infrastructure
  • Electric Vehicles
  • Consumer Electronics
  • Renewable Energy
  • Grid Balancing
  • Paints and coatings products
  • Li Battery
  • Detergents and personal care products

Moats

TCPCL is one of the few companies globally that uses Electrolysis process in organic synthesis. Advanced chemistries in process and for commercial development, manufacture and approvals, it takes 1-6 years for new players to enter this field.

In many of the segments, it is amongst top five players

Strengths

Considering the wide range of applications of our products, TCPCL can cater to customers across wide spectrum of Chemical Industries
which ensures a sustainable business model.
Diversified product portfolio has helped accelerate growth and in innovating and thus retain both new and existing customers

Diversified esteemed clientele

Necessary certifications in place : ISO 9001:2015 ISO 14001:2015 BS OHSAS 18001:2007

Advantages of Electrolyses

  • Electrolysis is considered as a ‘green’ chemistry process wherein apart from a single starting raw material, the process largely uses only water and electricity
  • Since no additional solvents or other chemicals are used, it is a safe chemistry
  • It has minimum requirement of auxiliary substances
  • The process enables faster output and Higher Purity
  • By deploying electrolysis, the products achieve the lowest possible process mass intensity

Region of operation 

The company exports most of its products to over 25 countries, including the US, China, Germany, Japan, South Africa and the UK.

It reduced % revenue dependency on top 10 customers from 60% to 47%

Shareholding

Promoter has sufficient skin in game with holding ~79% and other prominent players holding 10% more

Some triggers and updates from recent Q3Fy22 Concall

Getting approvals from two large customers

Getting into EV domain with supercapacitor batteries and new horizon opening up faster than anticipated

New versatile product development in Continuous flow chemistry us also capable in other applications including EV

Comfortable Leading market share in almost all operating domains

Mindset of accepting which projects

Risks (tried to see major risks, please do due diligence to understand more on this part)

Delayed expansion –currently scheduled for Nov 22

Delay in semiconductors supplies impacting SDA in FY23 as well (current anticipation is till FY22)

Slow ramp up of electrolyte salts than projected

Approvals for new PASC delayed

Increase in raw material and frieght costs is already impacting margins, further increase will hurt next two quarters badly in terms of margins if it happens ( Q4FY22, Q1FY23)

Valuations

They have to be seen in terms of huge growth runway available but current valuations don’t give that comfort to take large positions with risks on execution and inflation

Looks better to give time to company and see how it performs and keep accumulating in background in small tranches. That may work.

Your strategy can be different than mine. Your selection of company might be different than mine. So lets not be a BLIND FOLLOWER

Disclaimer – Analysis is NOT a BUY/SELL/HOLD Recommendation. It is for educational purpose and it can be used for educational purposes further. There could be lot of things which might have been missed in my analysis either due to lack of information or oversight etc.. Do your own diligence & contact your expert financial adviser before making any investment decision.

In case you have any questions/ queries, please feel free to reach me through Contact Form

Do spread the word among your peers, family members or anyone who can benefit from this blog and asked them to subscribe. But be selfish and take care of yourself first by subscribing before they do.

Enjoy the day and your life. Don’t forget, we are alone in this grand universe and may not get a chance to live again.

Environment · Medium Term trend · Mega trends · Technology

Technologies to watch by 2025

Five groups of technologies could attract $2 trillion of capital per year by 2025 and abate 40 percent of greenhouse-gas emissions by 2050.
Mckinsey
Electric Vehicles · Technology

Li-ion to Sodium ion batteries : Future is competitive